Is semaglutide FDA approved?
Yes — semaglutide is FDA-approved across multiple indications: type 2 diabetes (subcutaneous and oral formulations), chronic weight management in adults with obesity, and reduction of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. Research-supply semaglutide is sold for laboratory and bench-research applications only.
What the research literature says
Semaglutide’s regulatory pathway moved through the FDA approval process based on a substantial clinical-trial program developed by Novo Nordisk. The SUSTAIN program established the type 2 diabetes indication (SUSTAIN 1, PMID 28110911; SUSTAIN 7 head-to-head versus dulaglutide, PMID 29397376). The STEP program established the chronic weight management indication (PMID 33567185, PMID 32441473). The SELECT trial extended the cardiovascular-outcomes indication into obesity without diabetes (PMID 37952131).
The cardiovascular-outcomes data for type 2 diabetes patients with established cardiovascular disease was published earlier in the Marso trial (PMID 27633186). The compound’s safety profile across the cumulative clinical-trial dataset was reviewed in the Smits safety synthesis (PMID 34305810). The Aroda comparative-efficacy work consolidated the SUSTAIN program findings (PMID 30615985).
The research-supply form of semaglutide available through the Ronin catalog is supplied for laboratory and bench-research applications only. The FDA-approved pharmaceutical products are distinct — distributed through clinical-pharmacy channels with prescribing-information labels specific to the approved indications. Research-supply use does not imply clinical-use authorization.
Why this matters in research context
The extensive published clinical-trial dataset for semaglutide provides an unusually well-characterised pharmacological backdrop for research-supply protocols. Researchers can anchor experimental design to the substantial clinical-pharmacology data while operating within the research-use-only framework that governs the catalog supply form.
Related compounds
- Semaglutide 10mg — research-supply form
- Semaglutide (glossary entry) — clinical-trial overview, mechanism, dosing
Related research questions
- What is the half-life of semaglutide?
- Is tirzepatide FDA approved?
- How do semaglutide and tirzepatide differ?
References
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375(19):1834-1844. [PMID 27633186]
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol 2017;5(4):251-260. [PMID 28110911]
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989-1002. [PMID 33567185]
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389(24):2221-2232. [PMID 37952131]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Semaglutide is sold strictly as a research-grade reagent for laboratory and bench research applications.